{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-051371","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.670404+00:00","generated_at":"2026-05-23T19:49:00.167054+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MBX Biosciences appoints Steve Hoerter to board of directors","bullets":["Steven L. Hoerter appointed as independent director effective April 7, 2025.","Board expanded from 8 to 9 members; Hoerter designated as Class III director until 2027 AGM.","Hoerter is former CEO of Deciphera Pharmaceuticals (acquired by Ono for $2.4B in 2024).","Brings 30+ years pharma commercialization experience; also serves on boards of ORIC Pharmaceuticals and C4 Therapeutics.","Will receive standard non-employee director compensation and enter indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-051371","json":"https://secwatch.observer/filing/0000950170-25-051371.json","markdown":"https://secwatch.observer/filing/0000950170-25-051371.md","text":"https://secwatch.observer/filing/0000950170-25-051371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/0000950170-25-051371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/mbx-20250407.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:49:00.167054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36d3cd482f","claim":"Steven L. Hoerter was appointed as director at MBX Biosciences, Inc..","evidence_excerpt":"Effective as of April 7, 2025, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/0000950170-25-051371-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}